Assays for laboratory confirmation of novel human coronavirus (HCOV-EMC) infections by Corman, V.M. (Victor) et al.
1www.eurosurveillance.org
Rapid communications
Assays for laboratory confirmation of novel human 
coronavirus (hCoV-EMC) infections
V M Corman1,2, M A Müller1,2, U Costabel3, J Timm4, T Binger1, B Meyer1, P Kreher5, E Lattwein6, M Eschbach-Bludau1, A Nitsche5, T 
Bleicker1, O Landt7, B Schweiger5, J F Drexler1, A D Osterhaus8, B L Haagmans8, U Dittmer4, F Bonin3, T Wolff5,  
C Drosten (drosten@virology-bonn.de)1
1. Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
2. These authors contributed equally to this work
3. Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany
4. Institute of Virology, University of Duisburg-Essen, Essen, Germany
5. Robert Koch Institute, Berlin, Germany
6. Euroimmun AG, Lübeck, Germany
7. TibMolbiol, Berlin, Germany
8. Virosciences Laboratory, Erasmus MC, Rotterdam, the Netherlands
Citation style for this article: 
Corman VM, Müller MA, Costabel U, Timm J, Binger T, Meyer B, Kreher P, Lattwein E, Eschbach-Bludau M, Nitsche A, Bleicker T, Landt O, Schweiger B, Drexler JF, 
Osterhaus AD, Haagmans BL, Dittmer U, Bonin F, Wolff T, Drosten C. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro 
Surveill. 2012;17(49):pii=20334. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20334 
Article submitted on 05 December 2012 / published on 6 December 2012
We present a rigorously validated and highly sensi-
tive confirmatory real-time RT-PCR assay (1A assay) 
that can be used in combination with the previously 
reported upE assay. Two additional RT-PCR assays for 
sequencing are described, targeting the RdRp gene 
(RdRpSeq assay) and N gene (NSeq assay), where an 
insertion/deletion polymorphism might exist among 
different hCoV-EMC strains. Finally, a simplified and 
biologically safe protocol for detection of antibody 
response by immunofluorescence microscopy was 
developed using convalescent patient serum.
Introduction
A novel human coronavirus, hCoV-EMC, has recently 
emerged in the Middle East region [1-3]. The virus has 
caused severe acute respiratory infection (SARI) in at 
least nine patients to date. Latest reports from the 
World Health Organization (WHO) suggest that infec-
tions have occurred since April 2012, as hCoV-EMC was 
found retrospectively in two patients from a group of 11 
epidemiologically linked cases of SARI in Jordan, eight 
of whom were healthcare workers [4]. 
We have recently presented methods for the rapid 
detection of hCoV-EMC by real-time reverse transcrip-
tion polymerase chain reaction (RT-PCR) [2]. One of 
these protocols, the upE gene assay, has been used 
as a first-line diagnostic assay for all human cases to 
date. More than 100 laboratories worldwide have since 
been equipped with positive-control material neces-
sary to conduct the upE assay. We also presented a 
confirmatory RT-PCR assay targeting the open read-
ing frame (ORF) 1b gene, with slightly lower sensitivity 
than the upE assay. 
In view of the growing knowledge of the epidemiology 
of hCoV-EMC infections, WHO is continuously updating 
its guidelines for laboratory testing. During an expert 
consultation on 28 November 2012, it was concluded 
that first-line screening should involve the upE assay 
[2]. Confirmatory testing can involve any appropriately 
validated RT-PCR assay for alternative targets within 
the viral genome, followed by sequencing of at least a 
portion of one viral gene that can then be compared 
with hCoV-EMC sequences deposited in GenBank. 
Recent investigations into a cluster of cases in Saudi 
Arabia have revealed the possibility that the virus may 
not be detected by RT-PCR in all patients with symp-
toms and proven epidemiological linkage [5]. From our 
previous experience during the severe acute respira-
tory syndrome (SARS) epidemic in 2003, such issues 
were predicted to occur when testing by RT-PCR alone 
[2]. In SARS patients, in particular those seen more 
than 10 days after symptom onset, serological testing 
by immunofluorescence assay (IFA) has been success-
fully used to complement RT-PCR findings [6,7].
On 22 November 2012, German health authorities were 
notified of a patient who had been treated for SARI in a 
hospital in Essen, Germany [5]. On the basis of clinical 
samples from this case, we present here a set of vali-
dated assays for the confirmation of cases of hCoV-EMC 
infection, including a confirmatory real-time RT-PCR 
assay in the ORF1a gene, two sequencing amplicons in 
the RNA-dependent RNA polymerase (RdRp) and nucle-
ocapsid (N) protein genes, as well as a straightforward 
methodology for biologically safe immunofluorescence 
testing. 
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Methods
RT-PCR assays for the screening and 
confirmation of infections with hCoV-EMC
Figure 1 provides a summary of the target regions 
on the viral genome for screening, confirmation and 
sequence determination. Documentation on sources of 
materials used is provided in the Acknowledgements 
section.
RNA preparation
The procedures for RNA preparation have been 
described previously [2]. 
Confirmatory real-time RT-PCR 
assay in ORF 1a (1A assay)
A 25 µl reaction was set up containing 5 µl of RNA, 
12.5 µl of 2 X reaction buffer from the Superscript III 
one step RT-PCR system with Platinum Taq Polymerase 
(Invitrogen; containing 0.4 mM of each dNTP and 3.2 
mM MgSO4), 1 µl of reverse transcriptase/Taq mixture 
from the kit, 0.4 µl of a 50 mM MgCl2 solution (Invitrogen 
– not provided with the kit), 1 μg of non-acetylated 
bovine serum albumin (Sigma), 400 nM of primers 
EMC-Orf1a-Fwd (CCACTACTCCCATTTCGTCAG) and EMC-
Orf1a-Rev (CAGTATGTGTAGTGCGCATATAAGCA), as well 
as 200 nM of probe EMCOrf1a-Prb (6-carboxyfluores-
cein (FAM)-TTGCAAATTGGCTTGCCCCCACT -6-carboxy-
N,N,N,N´-tetramethylrhodamine (TAMRA)). Thermal 
cycling was performed at 55 °C for 20 min for the RT, 
followed by 95 °C for 3 min and then 45 cycles of 95 °C 
for 15 s, 58 °C for 30 s.
RT-PCR for generating amplicons 
for sequencing the RdRp gene 
target (RdRpSeq assay)
For the first round, a 25 µl reaction was set up contain-
ing 5 µl of RNA, 12.5 µl of 2 X reaction buffer from the 
Superscript III one step RT-PCR system with Platinum 
Taq Polymerase (Invitrogen; containing 0.4 mM of each 
dNTP and 3.2 mM MgSO4), 1 µl of reverse transcriptase/
Taq mixture from the kit, 0.4 µl of a 50 mM MgSO4 
 solution (Invitrogen – not provided with the kit), 1 μg 
of non-acetylated bovine serum albumin (Sigma), 400 
nM of each primer RdRpSeq-Fwd (TGC TAT WAG TGC 
TAA GAA TAG RGC; R=A/G, W=A/T) and RdRpSeq-Rev 
(GCA TWG CNC WGT CAC ACT TAG G; W=A/T, N=A/C/
T/G). Thermal cycling was performed at 50 °C for 20 
min, followed by 95 °C for 3 min and then 45 cycles of 
95 °C for 15 s, 56 °C for 15 s and 72 °C for 30 s, with a 
terminal elongation step of 72 °C for 2 min.
In cases where no amplification products were obtained 
with the RT-PCR assay, a 50 µl second-round reaction 
was set up containing 1 µl of reaction mixture from the 
first round, 5 µl of 10 X reaction buffer provided with 
the Platinum Taq Polymerase Kit (Invitrogen), 2 µl of a 
50 mM MgCl2 solution (provided with the kit), 200 µM 
of each dNTP, 400 nM concentrations of each second 
round primer RdRpSeq-Fwd (the same as in the first 
round) and RdRpSeq-Rnest (CAC TTA GGR TAR TCC CAW 
CCC A) and 0.2 μl of Platinum Taq from the kit. Thermal 
cycling was performed at 95 °C for 3 min and 45 cycles 
of 95 °C for 15 s, 56 °C for 15 s and 72 °C for 30 s, fol-
lowed by a 2 min extension step at 72 °C.
Figure 1
RT-PCR target regions for screening, confirmation and sequencing of novel human coronavirus (hCoV-EMC)
Orf1abOrf1a
15,049−15,290 18,266−18,347 27,458−27,550 29,549−29,860
E M NS
RdRpSeq1A ORF1b upE NSeq
11,197−11,280
N: nucleocapsid; Orf: open reading frame; RdRp: RNA-dependent RNA polymerase; RT-PCR: reverse transcription-polymerase chain reaction.
The figure shows the relative positions of amplicon targets presented in this study, as well as in [2]. Primers are represented by arrows, 
probes as blue bars. Numbers below amplicon symbols are genome positions according to the hCoV-EMC/2012 prototype genome presented 
in [1]. 
The 1A assay is the confirmatory real-time RT-PCR test presented in this study (target in the ORF1a gene). The RdRpSeq assay is a hemi-nested 
sequencing amplicon presented in this study (target in the RdRp gene). The ORF1b assay is a confirmatory real-time RT-PCR presented in 
[2]. The upE assay is a real-time RT-PCR assay recommended for first-line screening as presented in [2] (target upstrem of E gene). The NSeq 
assay is a hemi-nested sequencing amplicon presented in this study (target in N gene). 
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RT-PCR for sequencing in the N gene 
(NSeq assay)
The assay employed the same conditions as the 
RdRpSeq assay, except that the primer sequences were 
NSeq-Fwd (CCT TCG GTA CAG TGG AGC CA) and NSeq-
Rev (GAT GGG GTT GCC AAA CAC AAA C) for the first 
round and NSeq-Fnest (TGA CCC AAA GAA TCC CAA CTA 
C) and NSeq-Rev (the same as in the first round) for 
the second round. The second round was only done if 
no product was visible by agarose gel electrophoresis 
after the first round.
Virus quantification by real-time RT-
PCR using in-vitro transcribed RNA 
In-vitro transcribed RNA was prepared as described 
previously [2]. Serial 10-fold dilutions of this RNA 
were amplified in parallel with samples in a Roche 
LightCycler 480II after entering the known RNA con-
centrations of standards in the quantification mod-
ule of the operation software. Virus concentrations 
in terms of genome copies per ml of original sample 
were extrapolated using a conversion factor of 85.7, as 
explained previously [2].   
Virus growth, infection and titration
Virus stocks of the clinical isolate hCoV-EMC/2012 
(kindly provided by Ron Fouchier [1]) were grown on 
African green monkey kidney (Vero B4) cells. Cells 
were infected at a multiplicity of infection (MOI) of 0.01 
and supernatants were harvested two days post infec-
tion. Titres were determined by plaque assay on Vero 
B4 cells as described previously [8].
hCoV-EMC antibody detection assays
Two IFAs have been developed.
(i) Conventional IFA 
Vero cells were seeded onto glass coverslips in 24-well 
plates, grown to subconfluence, and infected at an MOI 
of 0.5. After 24 hours, cell monolayers were fixed with 
acetone [9]. 
(ii) Rapid, biologically safe IFA
Vero B4 cells in flasks were infected at an MOI of 0.01 
and harvested two days post infection. Infected cells 
were mixed with non-infected Vero B4 cells (ratio 1:1) 
and spotted on glass slides by dispensing and immedi-
ately aspirating the cell suspension. The concentration 
of the cell suspension was 10e7 cells per ml in medium. 
The time between dispensing and back-aspiration was 
2 seconds. About 6 wells could be loaded with the con-
tent of one 50 µl pipette tip. It was important for the 
success of cell spotting that the IFA slides used for the 
procedure should have undergone aggressive clean-
ing and autoclaving before use. After drying, the slides 
were fixed and virus inactivated with 4% paraformalde-
hyde for 30 minutes. Slides were immersed into ice-cold 
acetone/methanol (ratio 1:1) to permeabilise the cells. 
In the assay, patient sera (25 µl per dilution) were sub-
jected to serial dilution in sample buffer (Euroimmun 
AG, Lübeck, Germany) starting at 1:40 and applied at 
25 µl per well. As a positive control, a macaque-anti-
hCoV-EMC (day 14 post infection), provided by author 
B. H. was used in a 1:20 dilution. Slides were incubated 
at 37 °C for 1 hour (rapid slides) or at room temperature 
for 30 minutes (conventional coverslips) and washed 
three times with phosphate-buffered saline (PBS)-
Tween (0.1%) for 5 minutes. The secondary antibody 
was a goat-anti human Cy2-labelled immunoglobulin G 
conjugate. After incubation at 37 °C (spotted slides) or 
room temperature (conventional coverslips) for 30 min-
utes, they were washed three times with PBS-Tween for 
5 minutes, rinsed with water and mounted with DAPI 
ProLong mounting medium (Life Technologies).
Recombinant assays for confirmatory 
IFA and western blot analysis
The hCoV-EMC/2012 spike (S) and N genes were ampli-
fied from cDNA. For PCR amplification of FLAG-tagged 
N and S and subsequent cloning into a pCG1 vector 
(kindly provided by Georg Herrler, TIHO, Hannover), the 
following primers were used: 2c-nhCoV-SflagN-BamHI-F
(TACGGATCCGCCACCATGGATTACAAGGATGACGATGACAA 
GGGAGGCATACACTCAGTGTTTCTACTGATGT), 
2c-nhCoV-S-SalI-R (AGCGTCGACTTAGTGAACATGAAC
CTTATGCGG), 2c-nhCoV-NflagN-BamHI-F 
(TACGGATCCGCCACCATGGATTACAAGGATGACGATG
ACAAGGGAGGCGCATCCCCTGCTGCACCTCGT) 
and 2c-nhCoV-N-XbaI-R 
(AGCTCTAGACTAATCAGTGTTAACATCAATCATTG).
For IFA, Vero B4 cells were transfected in suspension 
using 0.5 µg of plasmid DNA and the FuGENE HD proto-
col (Roche, Basel, Switzerland). Transfected cells were 
seeded into a 24-well plate containing glass coverslips. 
After 24 hours, cells were fixed with 4% paraformalde-
hyde, washed twice with PBS-Tween and permeabilised 
with PBS containing 0.1% Triton X-100. For western blot 
analysis of recombinant spike and nucleocapsid pro-
teins, transfections were performed similarly but in 
six-well plates with HEK-293T cells using 2 µg of plas-
mid DNA. After 24 hours post-transfection, cells were 
washed three times with ice-cold PBS and harvested 
for western blot analysis. Cell lysis was performed with 
RIPA lysis buffer containing Protease Inhibitor Cocktail 
III (Calbiochem, San Diego, United States), 5mM DTT 
and nuclease (25 U/ml). Lysates from untransfected 
HEK-293T cells were used as controls. Patient serum 
was serially diluted 1:100 to 1:8,000 in PBS-Tween 
with 1% milk powder. Blot strips were incubated for 
1.5 hours at room temperature. The secondary anti-
body, a horseradish peroxidase-conjugated goat-anti 
human immunoglobulin, was applied (1:20,000 in PBS-
Tween with 1% milk powder). Detection was performed 
by using SuperSignal West Pico Chemiluminescence 
Substrate (Pierce Biotechnology).
Results
1A assay
The 1A RT-PCR assay is directed to the Orf1a gene: 
this was optimised for sensitivity by testing several 
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different candidate primers. The assay was compared 
with the upE assay by testing dilution series of the 
cell culture supernatant containing hCoV-EMC. There 
was complete concordance of the endpoints of the two 
assays. A total of 40 reactions using water instead of 
RNA were performed, in order to exclude any artifi-
cial signals due to irregular primer-/probe hybridisa-
tions. In-vitro transcribed RNA was generated for the 
peri-amplicon region of the 1A assay and used for 
parallel end-point dilution testing and probit regres-
sion analysis. The target concentration at which >95% 
of 1A assays can be expected to yield positive results 
was 4.1 RNA copies per reaction tube, i.e. a sensitivity 
equivalent to that of the upE assay ([2] and Figure 2). To 
exclude the possibility of false-positive results, human 
coronaviruses 229E, NL63, OC43, as well as SARS-CoV 
were tested in form of cell-culture supernatants in both 
assays (Table). A total of 42  clinical samples known to 
contain other respiratory viruses were tested as well, 
eight of which contained human coronaviruses includ-
ing the unculturable hCoV-HKU1: all samples yielded 
negative results (Table).
   
For a final comparison of sensitivity, the upE, ORF1b, 
and 1A assays were applied in parallel reactions to 
test a bronchoalveolar lavage sample from the patient 
treated in Essen, Germany. This sample had a very low 
RNA concentration of 360 copies per ml as determined 
with the upE assay using in-vitro transcribed RNA as 
the quantification standard [2]. The upE and 1A assays 
consistently detected RNA in this sample in repeated 
tests. The concentration determined by the 1A assay 
was between 66.5 and 100 copies per ml, reflecting 
Figure 2
Technical limit of detection for the 1A assay, novel human 
coronavirus (hCoV-EMC)
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The 1A assay is the confirmatory real-time RT-PCR test presented in 
this study (target in ORF1a). 
Probit regression analysis using results from parallel runs of the 1A 
assay containing very low concentrations of in-vitro transcribed 
hCoV-EMC RNA (between 50 and 0.3 average copies per reaction, 
16 parallel determinations per datum point).
Table 
Summary of experiments to determine sensitivity and cross-reactivity, novel human coronavirus (hCoV-EMC)
Experiment ORF1b assay 
Technical limit of detectiona 4.1 RNA copies/reaction(95% CI: 2.8– 9.5)
Cross-reactivity with hCoV-229E No reactivity with virus stock containing 10
5 PFU/ml 
(3 x 109 RNA copies/ml)
Cross-reactivity with hCoV-NL63 No reactivity with virus stock containing 10
6 PFU/ml 
(4 x 109 RNA copies/ml)
Cross-reactivity with hCoV-OC43 No reactivity with virus stock containing 10
4 PFU/ml 
(1x 108 RNA copies/ml)
Cross-reactivity with SARS-CoV No reactivity with virus stock containing 3 x 10
6 PFU/ml 
(5 x 1010 RNA copies/ml)
Cross-reactivity with clinical samples 
containing respiratory viruses 
No reactivity with 42 samples containing the following viruses: hCoV-HKU1 (n=3 samples); hCoV-OC43 
(n=1); hCoV-NL63 (n=3); hCoV-229E (n=1); human rhinovirus (n=2); enterovirus (n=4); human 
parechovirus (n=3); human metapneumovirus (n=4); respiratory syncytial virus (n=3); parainfluenza 
virus 1, 2, 3, 4 (n=7); influenza A virus (n=5); influenza B virus (n=2); adenovirus (n=4)
PFU: plaque-forming units.
a Defined as the novel human coronavirus (hCoV-EMC) RNA concentration at which >95% of parallel tests will return positive results.
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slightly lower target abundance in the non-structural 
gene RNA, as observed previously for SARS-CoV [10]. 
Critically, the ORF1b assay presented in [2] did not 
detect virus in this sample. 
RdRpSeq and NSeq assays
Two different RT-PCRs to produce amplicons for 
sequencing were designed. One amplicon was from 
the RdRp gene, a common target for CoV detection 
and a genome region where sequences for most cor-
onaviruses are available (RdRpSeq assay, Figure 1). 
The assay was designed to provide broad detection of 
Betacoronavirus clade C sequences including hCoV-EMC 
as well as related viruses from animal sources such as 
bats (unpublished observations). The other amplicon 
was from a highly specific fragment within the hCoV-
EMC N gene (NSeq assay, Figure 1). This region was 
chosen because it comprised a two amino acid (6 nt) 
deletion in the corresponding sequence published 
from a patient treated in London, United  Kingdom [11]. 
As shown in Figure 3, both amplicons were sensitive 
enough to detect cell culture-derived virus at very low 
concentrations. Both assays also yielded amplification 
products from the bronchoalveolar lavage sample from 
the Essen patient, in spite of its very low RNA concen-
tration. Sequencing results are shown in Figure 4. 
hCoV-EMC antibody detection
Finally, slides for immunofluorescence microscopy 
were produced following two different common pro-
tocols. While the first method, growing cells on cov-
erslips, provides better cell morphology, the second 
is commonly used to circumvent the necessity to opti-
mise infection dose and duration, and to obtain slides 
with no infectious virus, to meet the biosafety require-
ments for shipment. For the first (conventional) proto-
col, Vero cells were seeded on microscope coverslips 
and infected with virus in situ. Infection conditions had 
been previously optimised to ensure infection of about 
30% of cells in a series of experiments. For the second 
option, Vero cells were infected in conventional cell 
culture and mixed with an equivalent quantity of unin-
fected cells, after which they were spotted on glass 
microscope slides and further inactivated with para-
formaldehyde. Both types of slides were stained with 
serum of a cynomolgus macaque infected with hCoV-
EMC or with serum from the Essen patient. Figure 5, 
panel A, shows a typical coronavirus cytoplasmic fine-
to-medium granular fluorescence with pronounced 
perinuclear accumulation, sparing the nucleus on the 
coverslip culture. The same result was also achieved 
with the convalescent serum from an experimentally 
infected cynomolgus macaque, suggesting that this 
Figure 3
Comparison of RdRpSeq and NSeq assays, novel human coronavirus (hCoV-EMC)
BAL: bronchoalveolar lavage; BP: base pairs; N: nucleocapsid; NTC: No template control; RdRp: RNA-dependent RNA polymerase; PFU: plaque-
forming units; RT-PCR: reverse transcription-polymerase chain reaction.
RT-PCR amplification of sequencing fragments within the RdRp gene (panel A, RdRpSeq assay) and N gene (panel B, NSeq assay). Cell culture 
stock solutions of hCoV-EMC were diluted to the virus concentrations specified (in PFU per ml), of which 50 µl were extracted using the 
Qiagen Viral RNA mini kit and tested with both assays. The NSeq assay is more sensitive than the RdRpSeq assay. Both assays detected 
virus in a BAL sample from the Essen, Germany, patient. 
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Figure 4
Sequence alignments comparing the results of RdRpSeq and Nseq sequencing assays, novel human coronavirus (hCoV-EMC) 
and sequence obtained from a patient from Essen, Germany
Panel A. Results from the RdRpSeq assay on the Essen patient. 
Panel B. Results of the Nseq assay. 
Dots represent identitical nucleotides, hyphens represent sequence gaps. 
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can be used as a valid positive control in absence of 
available patient material. Figure 5, panel B, shows 
results from two convalescent sera of the patient, taken 
about four weeks apart, on simplified biologically safe 
slides. As expected, the fluorescence pattern was less 
well differentiated compared with slides infected and 
tested in situ. However, a very clear cytoplasmic peri-
nuclear pattern is discernible, suggesting those slides 
will be appropriate for diagnostic application in spite 
of their simpler production and safer handling. 
Sera from a limited number of German blood donors 
were tested by this IFA assay, with no relevant false-
positive findings in a non-exposed population. 
However, much more validation is needed, because 
antibodies against betacoronaviruses are generally 
known to cross-react within the genus.  Sera from 
patients with a high antibody titre against any other 
human coronavirus such as OC43 or HKU1 may well 
lead to false-positive results if tested by IFA alone.  We 
propose to use this IFA only for patients with a very 
clear epidemiological linkage, ideally presenting posi-
tive results with a first-line assay such as upE. Paired 
sera should be investigated wherever possible. 
As shown in Figure 5, panel C, IFA reactivity was also 
demonstrated in cells overexpressing recombinant S or 
N proteins. Anti-S and anti-N antibodies were also con-
firmed by western blot. 
Discussion
Here we present nucleic acid-based and serological 
assays for the confirmation of hCoV-EMC infections. 
The current strategy and recommendations by WHO 
require reference laboratories to be involved in cases 
where first-line screening has provided positive results. 
However, with the potential occurrence of more cases 
of hCoV-EMC infection, the demand for confirmatory 
testing might grow in a way that it could overwhelm the 
capacity of reference laboratories. The major challenge 
in setting up confirmatory methodology will be the val-
idation of tests. Technical studies can be tedious and 
clinical validation is hard to achieve if no patient sam-
ples are at hand. The documentation here of proven 
methodology is presented with those laboratories in 
mind that will have to provide diagnostic testing and 
additional reference services in the future, but cannot 
rely on their own validation studies.
The 1A real-time RT-PCR assay provides the same sen-
sitivity as the upE first-line assay, and should provide 
consistent results in case of truly positive patients. 
It should be mentioned that the ORF1b assay along 
with the upE assay can also serve as a highly robust 
confirmatory test [2]. However, patients may be seen 
at times when they excrete small amounts of virus, 
e.g. very early or very late after symptom onset [6]. 
Moreover, samples may be diluted due to clinical pro-
cesses such as lavage, as exemplified by the case 
investigated here. In such instances, confirmatory 
assays must have the same sensitivity as the first-line 
Figure 5
Examples of serological assays, novel human coronavirus 
(hCoV-EMC)
A Macaque serum
(1:20)
1:1,6001:4001:1001:40
B
Serum
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Panel A. Conventional immunofluorsecence assay (IFA) using 
cells grown and infected on coverslips. The patient serum from 
the later time point (23/11/12) was tested positive in a 1:1,000 
dilution. As control, a serum of an hCoV-EMC/2012 infected 
macaque (taken 14 days post infection) was applied. 
Panel B. Rapid/biologically safe immunofluorescence assay (IFA) 
slides. Mixed infected and non-infected Vero cells incubated 
with serially diluted sera from an hCoV-EMC-infected patient 
taken at two different time points post infection.
Panel C. IFA using Vero cells expressing recombinant spike and 
nucleocapsid proteins, as well as western blot against lysates 
from the same transfected cells. 
Bars represent 20 µm.
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test. Such high sensitivity is achieved by the 1A assay, 
providing an appropriate complement to the upE assay 
proposed previously [2]. 
While real-time RT-PCR products can be sequenced, the 
shortness of their fragments makes DNA preparation 
inefficient and limits the length of useful sequence 
information. We present here two different sequencing 
amplicons (RdRpSeq and NSeq assays) that will yield 
reasonably large fragments even from samples contain-
ing very low virus concentration. We are not proposing 
to preferentially use either of those two assays, as both 
have different properties that suggest using them in 
combination. The RdRpSeq assay provides sequencing 
results that can be compared with a large database of 
cognate sequences, as it is commonly used for typing 
coronaviruses. The amplicon overlaps to a large extent 
with that proposed earlier by Vijgen et al. for pan-
coronavirus detection, ensuring good comparability 
between laboratory results from different groups [12]. 
The primers of the RdRpSeq assay are highly conserved 
and will cross-react with other betacoronaviruses 
including hCoV-OC43 or -HKU1. Critically, this ampli-
con should not be used for screening if not connected 
with subsequent sequence analysis, as false-positive 
results are possible in patients infected with other 
human coronaviruses. In contrast, the NSeq assay pro-
vides highly sensitive and specific detection for hCoV-
EMC, enabling a sequence-based confirmation even for 
cases that present with very low virus concentration. 
Here it is interesting to note that a sequence presented 
from a patient treated in London has a deletion in the 
amplified fragment. We should not draw early conclu-
sions on virus diversity from these limited data, but it 
will be interesting to sequence and compare the NSeq 
fragment from more viruses in the future, in order to 
determine whether lineages with and without the dele-
tion might have formed already. The NSeq assay might 
be used as a tool for provisional strain classification in 
the future.
For the augmentation of confirmatory testing by serol-
ogy, IFA, ideally in paired sera taken several days 
apart, proved highly robust during the SARS epidemic 
[6,7]. In contrast to EIA, IFA provides additional crite-
ria for result interpretation via the localisation of sig-
nals within cells. False-positive reactivity can thus be 
circumvented. The data presented here are intended 
as reference for those laboratories willing to confirm 
cases of hCoV-EMC infection by IFA. We have shown in 
this single patient that antibodies were detectable by 
IFA at a time when the patient still presented severe dis-
ease and the virus was not yet eliminated from respira-
tory secretions as detectable by RT-PCR (case report to 
be presented elsewhere). As in many SARS patients, 
the antibody titre was in the medium range, below 
1:1,000, even in convalescence [6]. In SARS patients, 
IFA seroconversions usually began to show from day 
10 of symptoms onward, while virus RNA could not be 
detected by RT-PCR in respiratory secretions starting 
from day 15 onward [6,7]. 
It is important to mention that IFA slides contain 
virus-infected cells which in theory could retain infec-
tious virus. However, it has been shown in a meticu-
lous investigation of SARS-CoV that acetone fixation 
of IFA slides results in the reduction of infectivity to 
undetectable levels. The extent of reduction of infec-
tivity was at least 6.55 log 10 infectious virus doses 
[9] (greater reductions could not be measured by the 
assay applied). In the rapid and biologically safe IFA 
procedure we presented here, further reduction of 
any conceivable residues of infectivity was achieved 
by combining acetone fixation with paraformaldehyde 
treatment. This treatment was shown to confer effi-
cient reduction on SARS-CoV [9] and is also effective 
against other enveloped RNA viruses [13]. No residual 
infectivity should exist in the rapid and biologically 
safe IFA slides described here.  
We have also shown that there is good correlation 
between IFA results and western blot against the two 
major structural proteins, S and N. Western blotting 
might therefore be an option as a confirmatory diag-
nostic for serology. However, in absence of data from 
a considerably larger number of patients, care must 
be taken in interpreting the results from western blot 
alone, as SARS patients were found to vary in their 
immune responses against single proteins in western 
blot [14,15]. Not only western blot but also neutrali-
sation tests should be evaluated for their capacity to 
afford a highly specific confirmation of serological 
results [7]. This is of particular importance because it 
is unknown to what extent hCoV-EMC antibodies cross-
react with those against common human coronaviruses 
such as OC43 and HKU1. In the present study, we have 
not investigated cross-reactivity in a larger group of 
patients, as this requires meticulous counter-testing 
and selection of samples with high titres against other 
human coronaviruses, as well as confirmation by addi-
tional methods such as differential virus neutralisation 
tests. The serological data presented here should be 
regarded as suggestions for confirmatory testing of 
epidemiologically linked individuals, or of cases under 
investigation due to positive results in first-line tests. 
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